Scarica l'app Stockscreener
16.36
1.27%
-0.21
Dopo l'orario di chiusura:
15.79
-0.57
-3.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.57
Aprire:
$16.25
Volume 24 ore:
1.56M
Relative Volume:
0.88
Capitalizzazione di mercato:
$1.86B
Reddito:
-
Utile/perdita netta:
$-284.08M
Rapporto P/E:
-9.191
EPS:
-1.78
Flusso di cassa netto:
$-234.65M
1 W Prestazione:
+1.05%
1M Prestazione:
+30.46%
6M Prestazione:
+283.14%
1 anno Prestazione:
+44.14%
Intervallo 1D:
$15.94
$16.75
Intervallo di 1 settimana:
$15.26
$16.99
Portata 52W:
$3.72
$16.99
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Confronta COGT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
16.36 | 2.16B | 0 | -284.08M | -234.65M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Relative strength of Cogent Biosciences Inc. in sector analysisJuly 2025 Catalysts & Entry and Exit Point Strategies - newser.com
Is Cogent Biosciences Inc. stock a buy before product launchesGold Moves & Real-Time Price Movement Reports - newser.com
How strong is Cogent Biosciences Inc. stock revenue growthMarket Risk Report & Free Reliable Trade Execution Plans - newser.com
Visualizing Cogent Biosciences Inc. stock with heatmapsMarket Volume Summary & Expert Curated Trade Setups - newser.com
Stifel Initiates Coverage on Cogent Biosciences (COGT) with Hold Rating | COGT Stock News - GuruFocus
Is Cogent Biosciences Inc a good long term investmentQuarterly Earnings Review & Swing Trade Smarter With Data Insights - earlytimes.in
Cogent Biosciences Inc Stock Analysis and ForecastSector Leadership Analysis & Superior Wealth Building - earlytimes.in
Volume spikes in Cogent Biosciences Inc. stock – what they meanTrade Analysis Report & Low Drawdown Investment Strategies - newser.com
Cogent Biosciences (NASDAQ:COGT) Stock Price Passes Below Fifty Day Moving Average of $12.64 - 富途牛牛
13 Biotech Stocks Charging Ahead With New 52-week HighsWill Near-term Catalysts Drive More Gains? - RTTNews
Momentum divergence signals in Cogent Biosciences Inc. chartJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com
Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results - FinancialContent
Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year HighWhat's Next? - MarketBeat
Cogent Biosciences stock hits 52-week high at 16.49 USD - Investing.com
Will Cogent Biosciences Inc. stock outperform tech sector in 2025Weekly Earnings Recap & Verified Momentum Stock Alerts - newser.com
Will Cogent Biosciences Inc. stock split attract more investorsJuly 2025 Outlook & Intraday High Probability Setup Alerts - newser.com
Sentiment analysis tools applied to Cogent Biosciences Inc.Trade Volume Report & Real-Time Buy Zone Alerts - newser.com
Cogent Biosciences, Inc. (COGT): Analyst Ratings Point To A Promising 30% Upside - DirectorsTalk Interviews
Will earnings trigger a reversal in Cogent Biosciences Inc.Dividend Hike & Stepwise Swing Trade Plans - newser.com
Visual trend scoring systems applied to Cogent Biosciences Inc.July 2025 Patterns & Fast Moving Trade Plans - newser.com
Cogent Biosciences (NASDAQ:COGT) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Cogent Biosciences Inc. stock outlook for YEARJuly 2025 Catalysts & Weekly Setup with ROI Potential - newser.com
Cogent Biosciences (NASDAQ:COGT) Hits New 52-Week HighHere's Why - MarketBeat
Historical volatility pattern of Cogent Biosciences Inc. visualizedEarnings Risk Report & High Yield Stock Recommendations - newser.com
Published on: 2025-10-05 05:47:04 - newser.com
When is the best time to exit Cogent Biosciences Inc.CEO Change & Daily Entry Point Alerts - newser.com
Cogent Biosciences Relocates Headquarters to BXP’s 180 CityPoint - Connect CRE
Cogent Biosciences patents new GTPase KRAS inhibitors - BioWorld MedTech
Published on: 2025-10-03 00:35:36 - newser.com
Is Cogent Biosciences Inc. building a consolidation basePortfolio Return Report & Precise Trade Entry Recommendations - newser.com
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cogent Biosciences stock hits 52-week high at 14.55 USD By Investing.com - Investing.com Nigeria
Cogent Biosciences stock hits 52-week high at 14.55 USD - Investing.com
Platinum Investment Management Ltd. Boosts Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Biotech planning to seek first-ever FDA approval signs new Waltham lease - The Business Journals
Cushman & Wakefield Arranges 31,500-Square-Foot Lease for Cogent Biosciences in Greater Boston - Cushman & Wakefield
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cogent Biosciences Inc Azioni (COGT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pinnow Cole | Chief Commercial Officer |
Jan 14 '25 |
Buy |
7.60 |
43,750 |
332,412 |
45,848 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):